Mogroside V exerts anti-inflammatory effect via MAPK-NF-κB/AP-1 and AMPK-PI3K/Akt/mTOR pathways in ulcerative colitis
Yaping Zhou, Zuomin Hu, Ye Fan, Tianyi Guo, Yi Luo, Wenshen Zhou, Dandan Qin, Yiping Tang, Fuliang Cao, Feijun Luo, Qinlu Lin
Abstract
To evaluate the anti-inflammatory function of mogroside V (MGV) and its molecular mechanism, dextran sulfate sodium (DSS)-induced colitis and lipopolysaccharide (LPS)-induced inflammation model were used in the study. Results indicated that MGV (100 mg/kg/day) supplementation in diet improved the health status of mice. Western blot results showed that MGV inhibited the expression pro-inflammatory factors of colonic tissues. MGV significantly reduced the expressions of pro-inflammatory cytokines in the LPS-stimulated RAW264.7 cells, also inhibited the phosphorylation of MAPKs. MGV promoted the activation of AMPK and inhibition the PI3K/Akt/mTOR pathway. Compound C (AMPK inhibitor) and SC79 (Akt activator) reversed the alleviating effect of MGV on the expression pro-inflammatory factors via a hub molecule of mTOR, indicating that MGV inhibits LPS-stimulated inflammation by triggering the AMPK-PI3K/Akt/mTOR pathway. Collectively, MGV can potentially be used in the treatments of ulcerative colitis, and it exerts anti-inflammatory effect via MAPK-NF-κB/AP-1 and AMPK-PI3K/Akt/mTOR pathways in ulcerative colitis.